How to Get Sermorelin: $36.00 a Vial, or a Prescription

Friction rises down this table and so does what you receive. The bottom row is the one most readers arrive already intending to use, which is why the page is ordered against that grain rather than with it.

Only the third row divides cleanly into dollars per milligram, which is worth remembering when a page tells you one route is cheaper than another. Two of these four do not publish a mass at all.

This is the part almost every competing page gets wrong, in one direction or the other, and the mechanism is worth stating precisely.

Sermorelin was an approved drug. EMD Serono marketed it as Geref under NDA 019863, a diagnostic presentation of 0.05 mg per ampoule with submissions dating from 1991, and NDA 020443, a therapeutic presentation of 0.5 mg and 1 mg per vial approved on 1997-09-26. Both applications now show a marketing status of Discontinued, and the FDA product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. There is no current US label, and DailyMed returns no labelling for it.

Section 503A allows a compounding pharmacy to work from a bulk substance that is a component of an FDA-approved drug product, even where no monograph exists. Sermorelin acetate was a component of exactly such a product, so the discontinuation of Geref did not close the compounding path behind it.

The contrast is what makes this concrete. FDA publishes a Category 2 list of bulk substances that may present significant safety risks. Ibutamoren mesylate appears on it under both 503A and 503B, ipamorelin acetate appears under 503B, and GHRP-2, GHRP-6 and kisspeptin-10 appear as well. Others, among them BPC-157, Melanotan II, Semax, MOTS-c and epitalon, were nominated and later withdrawn. Sermorelin is absent from the Category 2 list entirely, active sections and withdrawn ones alike. Our prescription page walks the route in detail.

The research route has effectively no gate. That is its appeal and it is also the entire critique of it: nothing in the transaction assesses whether the purchase makes sense.

What it does supply is a document you can read before paying, which is more than most channels offer. On lot 38-01260229 that document reports 99.79 % purity by HPLC-UV-MS across 4 detected peaks, a measured quantity of 11.31 mg against a 10 mg label, an analysis date of 2026-02-07 at MZ Biolabs in Tucson, Arizona, and a named analyst.

What it does not supply is equally specific. There is no endotoxin test and no sterility test on that certificate. Scope is a property of the lot rather than the vendor, so a later lot might carry more, and the only way to know is to read the document attached to it. There is also no evaluation, no monitoring and no clinician, and the material is labelled for laboratory research rather than for human use.

Priced against that, $3.60 per labelled milligram is a rate for powder and a document. It is not a rate for a course of anything, and treating it as one is the error the whole category makes. Our listing-reading page goes field by field through what a listing does and does not commit to.

There is a fourth answer people expect and it is not available: walking into a retail pharmacy and collecting an approved product. No current US label exists, so there is nothing for a pharmacy to dispense off the shelf and nothing for an insurer to adjudicate against.

That absence is regularly misreported in both directions. Pages that call the compound banned or unapproved are describing a status it does not have, since the FDA record shows two approvals and a discontinuation explicitly not taken on safety or effectiveness grounds. Pages that describe it as an approved therapy available today are describing a product that stopped being marketed. Both errors are avoidable by reading the same product record.

The practical consequence for a buyer is narrow and worth stating plainly: there is no formulary position, no national drug code in current use and therefore no copay to compare against $36.00. Every figure quoted anywhere for this compound is a cash figure, whether it comes from a research storefront or a clinic.

A friction ranking is only useful if it resists inventing the numbers it lacks, so here is what can and cannot be quantified.

• Can be quantified. The vial. $99.99 list, $72.00 site price, $36.00 with the code, which is $10.00, $7.20 and $3.60 per labelled milligram. Quantity tiers take 3 %, 5 % or 10 % off list separately, and free carriage starts at $250.
• Cannot be quantified here. Consultation fees, laboratory panels and pharmacy fill prices. These vary by prescriber, by state and by pharmacy, and no published figure covers them the way a product page covers a vial. This site does not publish a monthly cost it cannot source.
• Cannot be quantified by anyone. The value of an evaluation you did not have. That is the real difference between the routes and it does not reduce to a rate.

What can be said structurally is that the prescription route front-loads its cost in time and gatekeeping and the research route front-loads nothing at all. If a reader's objection to the first route is the friction rather than the money, that objection is worth examining, because the friction is the part doing the work.

Most people reading a page like this will buy the vial. Pretending otherwise would make the rest of the page dishonest, so here is the caveat that belongs with that decision.

The approved indications were paediatric growth hormone deficiency and pituitary diagnostics. The modern market sells adult vitality, sleep and body composition, and the literature does not cover that. PubMed returns 332 records mentioning the compound, 3 with it in the title and 29 tagged as clinical trials. Searched alongside anti-aging the count is zero. ClinicalTrials.gov registers no studies naming it, so any page citing a trial identifier is citing something that was never registered.

The three title papers are a 2006 review in Clinical Interventions in Aging on adult-onset growth hormone insufficiency (PMID 18046908), a 1999 BioDrugs review of use in children with idiopathic growth hormone deficiency (PMID 18031173), and a 2021 paper on recurrent glioma (PMID 33842627) that answers no buyer question at all.

A real regulatory route and a thin literature for the marketed use are both true at the same time. Anyone who tells you only one of those two things is selling you something. If the arithmetic is what you came for, our price page runs every division that can honestly be run.